JERUSALEM, Oct. 17, 2017 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a
clinical-stage pharmaceutical company focused on the development of
oral drug delivery systems, announced today the publication of a
new paper co-authored by Oramed's Chief Scientific Officer, Dr.
Miriam Kidron, Dr. Roy Eldor, Dr. Ehud
Arbit and Dr. Yael Greenberg-Shushlav. The paper,
"Additive Effect of Oral Insulin and an Oral GLP-1 Agonist on
Postprandial Glucose Excursions in a Porcine Model" has been
published in the Endocrinology, Diabetes and Metabolism Journal
(EDMJ).
The paper presents the results of a study which investigates the
concomitant pre-prandial delivery of enteric-coated oral insulin
(ORMD-0801) and oral exenatide (ORMD-0901) capsules in
pigs. The positive data from the study suggest an additive
effect when ORMD-0801 and ORMD-0901 are given in combination.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is
a technology pioneer in the field of oral delivery solutions for
drugs currently delivered via injection. Established in 2006,
Oramed's Protein Oral Delivery (PODTM) technology is
based on over 30 years of research by top scientists at
Jerusalem's Hadassah Medical
Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801). The Company completed
multiple Phase II clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration. In
addition, Oramed is developing an oral GLP-1 analog capsule
(ORMD-0901).
For more information, the content of which is not part of this
press release, please visit www.oramed.com.
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss the possible additive
effects of ORMD-0801 and ORMD-0901 in combination, our expected
clinical development programs and clinical trials or
revolutionizing the treatment of diabetes with our products. These
forward-looking statements are based on the current expectations of
the management of Oramed only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements,
including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the U.S. Securities and
Exchange Commission.
Company Contact
Oramed Pharmaceuticals
Josh Hexter
Office: +972-2-566-0001 ext. 2
US: +1-844-9 ORAMED ext. 2
E-mail: josh@oramed.com
View original
content:http://www.prnewswire.com/news-releases/endocrinology-diabetes-and-metabolism-journal-publishes-scientific-paper-authored-by-oramed-scientists-300537779.html
SOURCE Oramed Pharmaceuticals Inc.